Introduction:

Hepatitis C constitutes a global public health problem due to its prevalence and progression to chronicity. The treatment of hepatitis C with direct-acting antiviral drugs has revolutionized the practice of clinical hepatology due to the possibility of curing the majority of patients with short treatments and without significant side effects.

Objective:

To characterize patients with hepatitis C who received treatment with direct-acting antiviral drugs in Camagüey province.

Methods:

A descriptive, cross-sectional and retrospective observational study was carried out in the Camagüey province during the period from January 4th, 2021 to March 28th, 2022. The universe of study consisted of 405 patients diagnosed with hepatitis C in the province. The sample was made up of 110 patients who underwent treatment with ribavirin and pegylated interferon and did not resolve as their charges continued to be detectable.

Results:

A predominance of patients with hepatitis C was observed in the age group of 55-59 years, male, with 1 to 3 years of diagnosis of the disease. Not all patients completed treatment due to the occurrence of deaths. Those who complied with the use of the direct-acting antiviral drugs sofosbuvir and daclatasvir during the 12 weeks, the vast majority of their viral loads were not detectable, mainly in the population, not so in the hemodialysis patients, although their figures decreased in relation to those who they had before starting treatment.

Conclusions:

The treatment turned out to be effective.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )